- Douglas R Galasko, University of California, San Diego
- Todd E Golde, University of Florida
- Philip Scheltens, VU University Medical Center
Affiliated to Alzheimer's Disease International (ADI), London, United Kingdom
Alzheimer's Disease International is the international federation of national Alzheimer organisations and global voice for dementia, leading and unifying the dementia community to provide global solutions to a global epidemic.
Levels of Chitinase-3-like protein 1 (YKL-40) are higher in mild cognitive impairment and Alzheimer’s disease patients; increased levels of YKL-40 and Visinin-like protein-1 (VILIP-1) may be associated with disease progression.
In this review, Walker and Lue evaluate which markers might better define different activation phenotypes of microglia in human brains and whether they fit into current microglial polarization schemes.
Those with type 2 diabetes, younger males with high non-diabetic HbA1c and adults with high stable blood glucose are at increased risk of poorer cognition and potentially increased risk of cognitive impairment.
Ottavio Arancio and colleagues summarise recent studies on human induced pluripotent stem cell (iPSC)-derived neurons and evaluate their use as a model for neurological diseases.
Brivaracetam, but not ethosuximide, was shown to reverse memory impairments in an Alzheimer’s disease (AD) mouse model, confirming a therapeutic role of anticonvulsant drugs targeting synaptic vesicle protein 2A across AD mouse models.
Colm Cunningham, Edel HennessyAlzheimer's Research & Therapy 2015, 7:33 (24 March 2015)
News from Alzforum
From the blog
Aims & scope
Alzheimer's Research & Therapy is the major forum for translational research into Alzheimer's disease. An international peer-reviewed journal, it publishes open access basic research with a translational focus, as well as clinical trials, research into drug discovery and development, and epidemiologic studies. The journal also provides reviews, viewpoints, commentaries, debates and reports. Although the primary focus is Alzheimer's dementia, the scope encompasses translational research into other neurodegenerative diseases.
The evolving field of traumatic brain injury
What do we currently know about chronic traumatic encephalopathy (CTE) and what are the most important questions in the field? Listen to a free podcast discussing this and more, as part of our special series on Traumatic Brain Injury.
Searching for biomarkers
As part of our special series on Peripheral Biomarkers, listen to a free podcast by Douglas Galasko about the advances and current issues in the search to identify blood biomarkers for Alzheimer's disease.